140 related articles for article (PubMed ID: 2544590)
21. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin.
Capranico G; Kohn KW; Pommier Y
Nucleic Acids Res; 1990 Nov; 18(22):6611-9. PubMed ID: 2174543
[TBL] [Abstract][Full Text] [Related]
22. DNA structural variations produced by actinomycin and distamycin as revealed by DNAase I footprinting.
Fox KR; Waring MJ
Nucleic Acids Res; 1984 Dec; 12(24):9271-85. PubMed ID: 6393053
[TBL] [Abstract][Full Text] [Related]
23. Protection of particular cleavage sites of restriction endonucleases by distamycin A and actinomycin D.
Nosikov VV; Braga EA; Karlishev AV; Zhuze AL; Polyanovsky OL
Nucleic Acids Res; 1976 Sep; 3(9):2293-301. PubMed ID: 967694
[TBL] [Abstract][Full Text] [Related]
24. Genomic sites of topoisomerase II activity determined by comparing DNA breakage enhanced by three distinct poisons.
Borgnetto ME; Tinelli S; Carminati L; Capranico G
J Mol Biol; 1999 Jan; 285(2):545-54. PubMed ID: 9878428
[TBL] [Abstract][Full Text] [Related]
25. Deletion and duplication sequences induced in CHO cells by teniposide (VM-26), a topoisomerase II targeting drug, can be explained by the processing of DNA nicks produced by the drug-topoisomerase interaction.
Ripley LS
Mutat Res; 1994 Apr; 312(2):67-78. PubMed ID: 7510833
[TBL] [Abstract][Full Text] [Related]
26. Distamycin A, a minor groove binder, changes enediyne-induced DNA cleavage sites and enhances apoptosis.
Hiraku Y; Oikawa S; Kawanishi S
Nucleic Acids Res Suppl; 2002; (2):95-6. PubMed ID: 12903122
[TBL] [Abstract][Full Text] [Related]
27. In vivo topoisomerase II cleavage of the Drosophila histone and satellite III repeats: DNA sequence and structural characteristics.
Käs E; Laemmli UK
EMBO J; 1992 Feb; 11(2):705-16. PubMed ID: 1311255
[TBL] [Abstract][Full Text] [Related]
28. Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Catapano CV; Carbone GM; Pisani F; Qiu J; Fernandes DJ
Biochemistry; 1997 May; 36(19):5739-48. PubMed ID: 9153414
[TBL] [Abstract][Full Text] [Related]
29. Drosophila topoisomerase II-DNA interactions are affected by DNA structure.
Howard MT; Lee MP; Hsieh TS; Griffith JD
J Mol Biol; 1991 Jan; 217(1):53-62. PubMed ID: 1846428
[TBL] [Abstract][Full Text] [Related]
30. Sequence-specific interactions of minor groove binders with restriction fragments of cDNAs for H tau 40 protein and MAP kinase 2. A qualitative and quantitative footprinting study.
Kittler L; Baguley BC; Löber G; Waring MJ
J Mol Recognit; 1999; 12(2):121-30. PubMed ID: 10398403
[TBL] [Abstract][Full Text] [Related]
31. Sequence selectivity of topoisomerase II DNA cleavage stimulated by mitoxantrone derivatives: relationships to drug DNA binding and cellular effects.
De Isabella P; Capranico G; Palumbo M; Sissi C; Krapcho AP; Zunino F
Mol Pharmacol; 1993 May; 43(5):715-21. PubMed ID: 8388987
[TBL] [Abstract][Full Text] [Related]
32. Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.
Bigioni M; Zunino F; Tinelli S; Austin CA; Willmore E; Capranico G
Biochemistry; 1996 Jan; 35(1):153-9. PubMed ID: 8555169
[TBL] [Abstract][Full Text] [Related]
33. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Ganapathi R; Grabowski D; Ford J; Heiss C; Kerrigan D; Pommier Y
Cancer Commun; 1989; 1(4):217-24. PubMed ID: 2576973
[TBL] [Abstract][Full Text] [Related]
34. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.
Thielmann HW; Popanda O; Gersbach H; Gilberg F
Carcinogenesis; 1993 Nov; 14(11):2341-51. PubMed ID: 8242865
[TBL] [Abstract][Full Text] [Related]
35. Analysis of eukaryotic topoisomerase II cleavage sites in the presence of the quinolone CP-115,953 reveals drug-dependent and -independent recognition elements.
Spitzner JR; Chung IK; Gootz TD; McGuirk PR; Muller MT
Mol Pharmacol; 1995 Aug; 48(2):238-49. PubMed ID: 7651357
[TBL] [Abstract][Full Text] [Related]
36. In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin.
Yang L; Rowe TC; Nelson EM; Liu LF
Cell; 1985 May; 41(1):127-32. PubMed ID: 2986841
[TBL] [Abstract][Full Text] [Related]
37. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.
Bugg BY; Danks MK; Beck WT; Suttle DP
Proc Natl Acad Sci U S A; 1991 Sep; 88(17):7654-8. PubMed ID: 1652758
[TBL] [Abstract][Full Text] [Related]
38. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells.
Yang L; Rowe TC; Liu LF
Cancer Res; 1985 Nov; 45(11 Pt 2):5872-6. PubMed ID: 2996763
[TBL] [Abstract][Full Text] [Related]
39. Enhancement and alteration of bleomycin-catalyzed site-specific DNA cleavage by distamycin A and some minor groove binders.
Yamamoto K; Kawanishi S
Biochem Biophys Res Commun; 1992 Feb; 183(1):292-9. PubMed ID: 1371920
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of site-specific topoisomerase II-mediated DNA cleavage by an N-methylpyrrolecarboxamide-anilinoacridine conjugate: relation to DNA binding.
Fossé P; René B; Saucier JM; Hénichart JP; Waring MJ; Colson P; Houssier C; Bailly C
Biochemistry; 1994 Aug; 33(33):9865-74. PubMed ID: 8060993
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
